Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-17T12:25:00.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11.
    Difference
    0.1%
    Check dated 2025-08-10T08:36:24.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.8%
    Check dated 2025-08-03T02:46:25.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, indicating an improvement or update in the content related to HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-07-26T23:29:29.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.1%
    Check dated 2025-07-19T18:53:22.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The web page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours beginning at 9 PM EDT.
    Difference
    0.8%
    Check dated 2025-07-12T12:51:36.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.